T cell-eosinophil crosstalk—A new road for effective immune checkpoint blockade in breast cancer?

Sharon Grisaru-Tal, Ariel Munitz*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

6 Scopus citations

Abstract

Immune checkpoint blockade (ICB) has revolutionized the landscape of cancer treatment. Nevertheless, most cancer patients still do not respond to ICB. In this issue of Cancer Cell, Blomberg et al. illustrate a critical cooperation between T cells and eosinophils, which jointly enhance effectiveness of ICB in breast cancer.

Original languageEnglish
Pages (from-to)9-11
Number of pages3
JournalCancer Cell
Volume41
Issue number1
DOIs
StatePublished - 9 Jan 2023

Funding

FundersFunder number
Azrieli Foundation Canada-Israel
Cancer Biology Research Center
Dotan Hemato Oncology fund
Richard Eimert Research Fund on Solid Tumors
U.S.-Israel Bi-national Science Foundation2015163
Israel Cancer Research Fund
Israel Cancer Association
Israel Science Foundation886/15, 542/20
Tel Aviv University

    Fingerprint

    Dive into the research topics of 'T cell-eosinophil crosstalk—A new road for effective immune checkpoint blockade in breast cancer?'. Together they form a unique fingerprint.

    Cite this